MorphoSys AG (MOR) 2017年年度报告「NASDAQ」.pdf

1、Annual Report 2017 MorphoSys AGannual reportlegend:mor program out-licensed mor program partnered discovery programProduct PipelineMorphoSyss Product Pipeline(March 8,2018)MOST ADVANCED DEVELOPMENT STAGEPROGRAM/PARTNER INDICATIONTremfya1(guselkumab)/Janssen/J&J Psoriasis Gantenerumab/Roche Alzheimer

2、s disease MOR208/not partnered Hematological malignancies Anetumab ravtansine(BAY94-9343)/Bayer Solid tumors BHQ880/Novartis Multiple myeloma Bimagrumab(BYM338)/Novartis Musculoskeletal diseases CNTO6785/Janssen/J&J Infl ammation MOR103(GSK3196165)/GlaxoSmithKline Infl ammation MOR202/I-Mab Biopharm

3、a2 Multiple myeloma NOV-12(MAA868)/Novartis Prevention of thrombosis Setrusumab(BPS804)/Mereo/Novartis Brittle bone syndrome Tesidolumab(LFG316)/Novartis Eye diseases Utomilumab(PF-05082566)/Pfi zer Cancer VAY736/Novartis Infl ammation Xentuzumab(BI-836845)/BI Solid tumors MOST ADVANCED DEVELOPMENT

4、STAGEPROGRAM/PARTNER INDICATIONBAY1093884/Bayer Hemophilia Elgemtumab(LJM716)/Novartis CancerMOR106/Galapagos Infl ammation MOR1073(LP2-3)/not partnered Not disclosedNOV-7(CLG561)/Novartis Eye diseasesNOV-8/Novartis Infl ammationNOV-9(LKA651)/Novartis Diabetic eye diseasesNOV-10(PCA062)/Novartis Can

5、cerNOV-11/Novartis Blood disordersNOV-13(HKT288)/Novartis CancerNOV-14/Novartis AsthmaPRV-300(CNTO3157)/ProventionBio Infl ammationVantictumab(OMP-18R5)/OncoMed Solid tumorsDISCOVERYPRECLINICPHASE 1PHASE 2PHASE 3MARKETDISCOVERYPRECLINICPHASE 1PHASE 2PHASE 3MARKET1 We still consider Tremfya a phase 3

6、 compound due to ongoing studies in various indications.2 For development in the Greater China market(China,Hong Kong,Taiwan,Macao).3 A phase 1 study in healthy volunteers was completed.MOR107 is currently in preclinical investigation with a focus on oncology indications.*In addition,7 proprietary p